232 related articles for article (PubMed ID: 18926092)
1. NCCN Task Force Report: mTOR inhibition in solid tumors.
Figlin RA; Brown E; Armstrong AJ; Akerley W; Benson AB; Burstein HJ; Ettinger DS; Febbo PG; Fury MG; Hudes GR; Kies MS; Kwak EL; Morgan RJ; Mortimer J; Reckamp K; Venook AP; Worden F; Yen Y
J Natl Compr Canc Netw; 2008 Sep; 6 Suppl 5():S1-20; quiz S21-2. PubMed ID: 18926092
[TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
3. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
4. Targeting mTOR for cancer treatment.
Rubio-Viqueira B; Hidalgo M
Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
[TBL] [Abstract][Full Text] [Related]
5. [mTOR inhibitors].
Oya M
Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
[TBL] [Abstract][Full Text] [Related]
6. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
7. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
8. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
Janus A; Robak T; Smolewski P
Cell Mol Biol Lett; 2005; 10(3):479-98. PubMed ID: 16217558
[TBL] [Abstract][Full Text] [Related]
9. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
Huang JJ; Lin TY
Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
[TBL] [Abstract][Full Text] [Related]
10. The role of mTOR in the management of solid tumors: an overview.
Strimpakos AS; Karapanagiotou EM; Saif MW; Syrigos KN
Cancer Treat Rev; 2009 Apr; 35(2):148-59. PubMed ID: 19013721
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
[TBL] [Abstract][Full Text] [Related]
12. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
Wang X; Zhan Y; Zhao L; Alvarez J; Chaudhary I; Zhou BB; Abraham RT; Feuerstein GZ
J Pharmacol Exp Ther; 2011 Nov; 339(2):421-9. PubMed ID: 21835932
[TBL] [Abstract][Full Text] [Related]
13. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
Khokhar NZ; Altman JK; Platanias LC
Curr Opin Oncol; 2011 Nov; 23(6):578-86. PubMed ID: 21892085
[TBL] [Abstract][Full Text] [Related]
14. Targeting the mTOR pathway using deforolimus in cancer therapy.
Mahalingam D; Sankhala K; Mita A; Giles FJ; Mita MM
Future Oncol; 2009 Apr; 5(3):291-303. PubMed ID: 19374536
[TBL] [Abstract][Full Text] [Related]
15. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Del Bufalo D; Ciuffreda L; Trisciuoglio D; Desideri M; Cognetti F; Zupi G; Milella M
Cancer Res; 2006 Jun; 66(11):5549-54. PubMed ID: 16740688
[TBL] [Abstract][Full Text] [Related]
17. The biology behind mTOR inhibition in sarcoma.
Wan X; Helman LJ
Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
[TBL] [Abstract][Full Text] [Related]
18. Targeting mTOR in renal cell carcinoma.
Hudes GR
Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
[TBL] [Abstract][Full Text] [Related]
19. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
Dancey JE; Curiel R; Purvis J
Semin Oncol; 2009 Dec; 36 Suppl 3():S46-58. PubMed ID: 19963100
[TBL] [Abstract][Full Text] [Related]
20. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
Brachmann S; Fritsch C; Maira SM; García-Echeverría C
Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]